SpePharm announces the acquisition of Savene from TopoTarget

04-Mar-2010 - SpePharm Holding, BV announced the acquisition of the worldwide (with the exception of North and South America) rights to Savene® from TopoTarget A/S. As part of the acquisition SpePharm will also take on the European sales force of TopoTarget. Savene®, which has been marketed by TopoTarget since ...

TopoTarget announces new CEO to prepare commercialisation of belinostat

25-Feb-2010 - TopoTarget A/S announced that Francois Martelet, MD, takes up the position of CEO of TopoTarget in order to add the necessary late-stage clinical development and marketing expertise to ensure a successful development and commercialisation of belinostat, TopoTarget's lead anticancer drug. Dr. ...

TopoTarget completes the capital increase and the acquisition of Apoxis SA

29-Jun-2007 - TopoTarget A/S announced the completion of the acquisition of Apoxis SA with 3,598,030 shares having been issued to the vendors of Apoxis. Hereby TopoTarget gains two oncology products to its pipeline. Consistent with the growth strategy pursued by TopoTarget, the acquisition of the Swiss biotech ...

TopoTarget and CuraGen Initiate Phase II Trial of Belinostat (PXD101) in Combination with Velcade

30-Mar-2007 - TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat (PXD101), a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade® ...

TopoTarget establishes TopoTarget USA, Inc. and employs experienced marketeer as President

17-Nov-2006 - TopoTarget A/S announced the establishment of TopoTarget USA, Inc. to be located in Rockaway, New Jersey near the center of the east coast U.S. pharmaceutical industry. TopoTarget USA, Inc. is scheduled to launch the company's first oncology product, Totect(TM), for the treat-ment of ...

TopoTarget and CuraGen Initiate NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer

16-Nov-2006 - TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ovarian cancer. This trial is being sponsored by the ...

Southwest Oncology Group Opens New Lymphoma Trial with CuraGen's and TopoTarget's PXD101

28-Aug-2006 - CuraGen Corporation and TopoTarget A/S announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. The agent, PXD101, will be evaluated in patients ...

CuraGen and TopoTarget Initiate Clinical Program Evaluating Oral Administration of PXD101

Phase I trial to establish the dose and frequency for oral PXD101 in patients with advanced solid tumors

14-Aug-2006 - CuraGen Corporation and TopoTarget A/S announced the initiation of a Phase I clinical trial evaluating the administration of oral PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. The Phase I trial will be led by Dr. W. Kevin Kelly, Associate ...

CuraGen and TopoTarget Initiate NCI-sponsored Phase I Clinical Trial of PXD101 and Azacitidine

10-Aug-2006 - CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine for the treatment of advanced hematologic ...

CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with PXD101 and Velcade(R) for Multiple Myeloma

24-Mar-2006 - CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade(R) (bortezomib) for the treatment of relapsed, refractory multiple ...